Last reviewed · How we verify
MEDI6570
At a glance
| Generic name | MEDI6570 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction (PHASE2)
- REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD (PHASE2)
- Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI6570 CI brief — competitive landscape report
- MEDI6570 updates RSS · CI watch RSS
- AstraZeneca portfolio CI